Botulinum Toxin Type A in Diabetic Peripheral Neuropathy
NCT ID: NCT05296759
Last Updated: 2022-04-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
30 participants
INTERVENTIONAL
2021-02-01
2022-03-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy
NCT07036796
Acetylcholine Iontophoresis As A New Challenge With Type 2 Diabetic Peripheral Neuropathy: A Possible New Therapy
NCT06219590
Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)
NCT01868191
Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy
NCT04322240
The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients
NCT06479629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
First group was add on duloxetine, second was add on gabapentin and the third group was injected intradermal with Botulinum toxin A. Base line Assessment before treatment and follow up assessment as performed The treatment options were explained to the patients and the choice of Botulinum toxin A Intradermal injection was the patient own decision based on inability to be tolerate or adhere to oral treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
botulinum toxin A injection
botulinum toxin A injection
botulinum toxin A
botulinum toxin A injection
gabapentin
gabapentin
Gabapentin
Gabapentin oral intake
duloxetine
duloxetine
Duloxetine
Duloxetine oral drug intake
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
botulinum toxin A
botulinum toxin A injection
Gabapentin
Gabapentin oral intake
Duloxetine
Duloxetine oral drug intake
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexandria University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eman Hamdy
Principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
faculty of medicine Alexandria university
Alexandria, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2217
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.